| Will Biosimilars Alter Biotech Landscape? Sydney Williams submits:Though flawed, the pathway for follow-on biologics establishes a new dialogue between the FDA and manufacturers, according to Steve Grossman of FDA Matters. It encourages different strategies for best-possible routes to market for follow-on, or biosimilar, products.Grossman states:Complete Story » seekingalpha.com |
Bristol-Myers Squibb: Attractive, With a Couple Hiccups Jason Chew submits: With a 5% dividend, Bristol-Myers Squibb (BMY) provides one the highest yields you can find. This makes BMY a very attractive stock for income investors, especially considering today’s near-zero interest rate environment.There are however, a couple hiccups for investors to be aware of. Bristol is set to lose patent protection on its best-selling drugs, Plavix in 2011, and Avapro in 2012. Plavix and Avapro had sales of $6.1 and $1.3 billion, respectively in 2009, together accounting for about 39% of all revenue. Some of this revenue will be made up by growth from its portfolio of approved drugs. Abilify, already a $2.6 billion drug, increased sales 20% in 2009, the virology franchise of Baraclude, Reyataz, and Sustiva total another $3.4 billion in sales and grew about 10% in the period. Orencia and Sprycel are also doing well, albeit from smaller bases. Both products have the potential to reach over $1 billion in sales. Recently launched Onglyza, however, is off to a rather slow start. I estimate growth from these products can make up for approximately 40% of the revenue lost by Plavix and Avapro by 2013.Complete Story » seekingalpha.com |
NeoGenomics Schedules its Q2 2010 Earnings Release for July 29, 2010 (PR Newswire) NeoGenomics, Inc. announced today that it plans to release its second quarter 2010 financial results on Thursday, July 29, 2010. us.rd.yahoo.com |
Every Mother, Every Child - Video Johnson & Johnson Aims to Help Up to 120 Million Women and Children Each Year Through Five-Year Commitment to U.N. Millennium Development Goals feedproxy.google.com |
Sanofi Takeover Offer for Genzyme: The Pressure Is On EP Vantage submits:With Genzyme (GENZ) digging its heels in and Sanofi-Aventis (SNY) refusing to raise its bid, taking the $69 a share offer straight to the US biotech’s shareholders was the logical next step for the French predator. Considering Genzyme's stock has been trading higher than this for the last month, few investors will now choose to sell. However, the hostile move will increase the pressure on the board of the US biotech to sit down and start talking seriously. For this is undoubtedly what Chris Viehbacher, Sanofi’s chief executive, wants: to get his feet under the negotiating table and be able to conduct some real due diligence.Complete Story » seekingalpha.com |